GHS-R1a is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Compared to the Basic Test it is more sensitive to operator technique, and as a result may be less precise. Acute Toxicity Solid-Phase Test is a procedure that allows the test organism to come in direct contact with the solid sample as particulate in an aqueous suspension. Normally, this test provides results indicating equal or higher toxicity when compared to eluate or pore water tests of the same sample. This is due to either equal or increased bioavailability resulting from direct contact. This test is subject to several sources of interference of luminescence including loss of bacteria from effects other than toxicity such as filtration of the sample; absorption of light due to color; and scattering of light due to turbidity. Corrections can be made by testing a sample of similar particle composition that is known to not be toxic. This test consists of two controls and 13 sample dilutions in duplicate. The Solid-Phase Test exposes the bacteria in such a way that is not always possible with pore water and elutriate. Acute Toxicity Comparison & Inhibition Tests are the best procedures for testing samples with a low level of toxicity when an ECxx can not be determined using the Basic Test. These protocols are recommended for testing waste water treatment plant effluent, stormwater runoff, drinking water, pore water, and eluate. These tests use multiple replicates of a sample at a single concentration. Similar to the Basic Test, the Comparison Test protocol uses zero time light readings used for correcting the timed light level readings.
== Sources == Hyaluronic acid can be made through three main processes: Animal sources, Microbial hyaluronic acid production and chemical synthesis. HA was originally extracted from bovine vitreous humor (gel from a cows eye) by Meyer and Palmer in 1934. HA was then also isolated from Pig skin, Human skin and rooster’s comb. The most common animal source is rooster’s comb due being a byproduct from the meat industry. However, challenges such as low yields, high production costs, and ethical issues associated with animal-derived HA has driven the development of microbial production methods for HA.
=== Contraindications and patient factors === Docetaxel is contraindicated for use with patients with a baseline neutrophil count less than 1500 cells/μL, a history of severe hypersensitivity reactions to docetaxel or polysorbate 80, severe liver impairment and pregnant or breast-feeding women. Side effects are experienced more frequently by patients of 65 years or older, but dosage is usually not decreased. Kidney failure is thought not to be a significant factor for docetaxel dosage adjustment. Patients with hepatic insufficiency resulting in serum bilirubin greater than the upper limit of normal (ULN) should not be administered docetaxel, though this is not a stated contraindication. Dosage should be reduced by 20% in people who develop grade 3 or 4 diarrhea following exposure to docetaxel, hepatotoxicity defined by liver enzymes at levels greater than five times the ULN, and grade 2 palmer-planter toxicity. Paediatric trials of docetaxel have been limited, and so safety of use in patients under 16 years has not been established.
Sources: en.wikipedia.org
=== Inorganic chemistry === Hydroxide precipitation is probably the most widely used industrial precipitation process in which metal hydroxides are formed by adding calcium hydroxide (slaked lime) or sodium hydroxide (caustic soda) as precipitant.
=== Hormones and genes === KRT37 is the only keratin that is regulated by androgens. This sensitivity to androgens was acquired by Homo sapiens and is not shared with their great ape cousins. Although Winter et al. found that KRT37 is expressed in all the hair follicles of chimpanzees, it was not detected in the head hair of modern humans. As androgens are known to grow hair on the body but decrease it on the scalp, this lack of scalp KRT37 may help explain the paradoxical nature of Androgenic alopecia as well as the fact that head hair anagen cycles are extremely long. Although it is generally accepted that male pattern baldness follows a pattern of autosomal dominant inheritance, more recent research has shown that approximately 80% of bald men have bald fathers. This is greater than would be expected if pattern balding were a purely autosomal trait, and may suggest that there is an important paternal route of inheritance, either through a Y-chromosome gene or a paternal imprinting effect.
Now EC 1.1.1.303, diacetyl reductase [(R)-acetoin forming] and EC 1.1.1.304, diacetyl reductase [(S)-acetoin forming] EC 1.1.1.6: glycerol dehydrogenase EC 1.1.1.7: propanediol-phosphate dehydrogenase EC 1.1.1.8: glycerol-3-phosphate dehydrogenase (NAD+) EC 1.1.1.9: D-xylulose reductase EC 1.1.1.10: L-xylulose reductase EC 1.1.1.11: D-arabinitol 4-dehydrogenase EC 1.1.1.12: L-arabinitol 4-dehydrogenase EC 1.1.1.13: L-arabinitol 2-dehydrogenase EC 1.1.1.14: L-iditol 2-dehydrogenase EC 1.1.1.15: D-iditol 2-dehydrogenase EC 1.1.1.16: galactitol 2-dehydrogenase EC 1.1.1.17: mannitol-1-phosphate 5-dehydrogenase EC 1.1.1.18: inositol 2-dehydrogenase EC 1.1.1.19: glucuronate reductase EC 1.1.1.20: glucuronolactone reductase EC 1.1.1.207: (-)-menthol dehydrogenase EC 1.1.1.208: (+)-neomenthol dehydrogenase EC 1.1.1.21: aldose reductase EC 1.1.1.22: UDP-glucose 6-dehydrogenase EC 1.1.1.222: (R)-4-hydroxyphenyllactate dehydrogenase EC 1.1.1.23: histidinol dehydrogenase| EC 1.1.1.24: quinate/shikimate dehydrogenase (NAD+) EC 1.1.1.25: shikimate dehydrogenase (NADP+) EC 1.1.1.26: glyoxylate reductase EC 1.1.1.27: L-lactate dehydrogenase EC 1.1.1.28: D-lactate dehydrogenase EC 1.1.1.29: glycerate dehydrogenase EC 1.1.1.30: 3-hydroxybutyrate dehydrogenase EC 1.1.1.31: 3-hydroxyisobutyrate dehydrogenase EC 1.1.1.32: mevaldate reductase EC 1.1.1.33: mevaldate reductase (NADPH) EC 1.1.1.34: hydroxymethylglutaryl-CoA reductase (NADPH) EC 1.1.1.35: 3-hydroxyacyl-CoA dehydrogenase EC 1.1.1.36: acetoacetyl-CoA reductase EC 1.1.1.37: malate dehydrogenase EC 1.1.1.38: malate dehydrogenase (oxaloacetate-decarboxylating) EC 1.1.1.39: malate dehydrogenase (decarboxylating) EC 1.1.1.40: malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) EC 1.1.1.41: isocitrate dehydrogenase (NAD+) EC 1.1.1.42: isocitrate dehydrogenase (NADP+) EC 1.1.1.43: phosphogluconate 2-dehydrogenase EC 1.1.1.44: phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating) EC 1.1.1.45: L-gulonate 3-dehydrogenase EC 1.1.1.46: L-arabinose 1-dehydrogenase EC 1.1.1.47: glucose 1-dehydrogenase [NAD(P)+)] EC 1.1.1.48: D-galactose 1-dehydrogenase EC 1.1.1.49: glucose-6-phosphate dehydrogenase (NADP+) EC 1.1.1.50: 3α-hydroxysteroid 3-dehydrogenase (Si-specific) EC 1.1.1.51: 3(or 17)β-hydroxysteroid dehydrogenase EC 1.1.1.52: 3α-hydroxycholanate dehydrogenase (NAD+) EC 1.1.1.53: 3α(or 20β)-hydroxysteroid dehydrogenase EC 1.1.1.54: allyl-alcohol dehydrogenase EC 1.1.1.55: lactaldehyde reductase (NADPH) EC 1.1.1.56: ribitol 2-dehydrogenase EC 1.1.1.57: fructuronate reductase EC 1.1.1.58: tagaturonate reductase EC 1.1.1.59: 3-hydroxypropionate dehydrogenase EC 1.1.1.60: 2-hydroxy-3-oxopropionate reductase EC 1.1.1.61: 4-hydroxybutyrate dehydrogenase EC 1.1.1.62: 17β-estradiol 17-dehydrogenase EC 1.1.1.63: testosterone 17β-dehydrogenase. Now EC 1.1.1.239, 3α(17β)-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.64: testosterone 17β-dehydrogenase (NADP+) EC 1.1.1.65: pyridoxine 4-dehydrogenase EC 1.1.1.66: ω-hydroxydecanoate dehydrogenase EC 1.1.1.67: mannitol 2-dehydrogenase EC 1.1.1.68: 5,10-methylenetetrahydrofolate reductase. Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.69: gluconate 5-dehydrogenase EC 1.1.1.70: D-glucuronolactone dehydrogenase. Now included with EC 1.2.1.3 aldehyde dehydrogenase (NAD+) EC 1.1.1.71: alcohol dehydrogenase [NAD(P)+] EC 1.1.1.72: glycerol dehydrogenase (NADP+) EC 1.1.1.73: octanol dehydrogenase EC 1.1.1.74: D-aminopropanol dehydrogenase (reaction due to EC 1.1.1.4 (R,R)-butanediol dehydrogenase) EC 1.1.1.75: (R)-aminopropanol dehydrogenase EC 1.1.1.76: (S,S)-butanediol dehydrogenase EC 1.1.1.77: lactaldehyde reductase EC 1.1.1.78: methylglyoxal reductase (NADH-dependent) EC 1.1.1.79: glyoxylate reductase (NADP+) EC 1.1.1.80: isopropanol dehydrogenase (NADP+) EC 1.1.1.81: hydroxypyruvate reductase EC 1.1.1.82: malate dehydrogenase (NADP+) EC 1.1.1.83: D-malate dehydrogenase (decarboxylating) EC 1.1.1.84: dimethylmalate dehydrogenase EC 1.1.1.85: 3-isopropylmalate dehydrogenase EC 1.1.1.86: ketol-acid reductoisomerase (NADP+) EC 1.1.1.87: homoisocitrate dehydrogenase EC 1.1.1.88: hydroxymethylglutaryl-CoA reductase EC 1.1.1.89: dihydroxyisovalerate dehydrogenase (isomerizing). Now included with EC 1.1.1.86 ketol-acid reductoisomerase EC 1.1.1.90: aryl-alcohol dehydrogenase EC 1.1.1.91: aryl-alcohol dehydrogenase (NADP+) EC 1.1.1.92: oxaloglycolate reductase (decarboxylating) EC 1.1.1.93: tartrate dehydrogenase EC 1.1.1.94: glycerol-3-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.95: phosphoglycerate dehydrogenase EC 1.1.1.96: diiodophenylpyruvate reductase EC 1.1.1.97: 3-hydroxybenzyl-alcohol dehydrogenase EC 1.1.1.98: (R)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.99: (S)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.100: 3-oxoacyl-[acyl-carrier-protein] reductase EC 1.1.1.101: acylglycerone-phosphate reductase EC 1.1.1.102: 3-dehydrosphinganine reductase EC 1.1.1.103: L-threonine 3-dehydrogenase EC 1.1.1.104: 4-oxoproline reductase EC 1.1.1.105: all-trans-retinol dehydrogenase (NAD+) EC 1.1.1.106: pantoate 4-dehydrogenase EC 1.1.1.107: pyridoxal 4-dehydrogenase EC 1.1.1.108: carnitine 3-dehydrogenase EC 1.1.1.109: Now EC 1.3.1.28, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.1.1.110: aromatic 2-oxoacid reductase EC 1.1.1.111: 3-(imidazol-5-yl)lactate dehydrogenase EC 1.1.1.112: indanol dehydrogenase EC 1.1.1.113: L-xylose 1-dehydrogenase EC 1.1.1.114: apiose 1-reductase EC 1.1.1.115: ribose 1-dehydrogenase (NADP+) EC 1.1.1.116: D-arabinose 1-dehydrogenase (NAD+) EC 1.1.1.117: D-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.118: glucose 1-dehydrogenase (NAD+) EC 1.1.1.119: glucose 1-dehydrogenase (NADP+) EC 1.1.1.120: galactose 1-dehydrogenase (NADP+) EC 1.1.1.121: aldose 1-dehydrogenase (NAD+) EC 1.1.1.122: D-threo-aldose 1-dehydrogenase EC 1.1.1.123: sorbose 5-dehydrogenase (NADP+) EC 1.1.1.124: fructose 5-dehydrogenase (NADP+) EC 1.1.1.125: 2-deoxy-D-gluconate 3-dehydrogenase EC 1.1.1.126: 2-dehydro-3-deoxy-D-gluconate 6-dehydrogenase EC 1.1.1.127: 2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase EC 1.1.1.128: The reaction described is covered by EC 1.1.1.264, L-idonate 5-dehydrogenase. EC 1.1.1.129: L-threonate 3-dehydrogenase EC 1.1.1.130: 3-dehydro-L-gulonate 2-dehydrogenase EC 1.1.1.131: mannuronate reductase EC 1.1.1.132: GDP-mannose 6-dehydrogenase EC 1.1.1.133: dTDP-4-dehydrorhamnose reductase EC 1.1.1.134: dTDP-6-deoxy-L-talose 4-dehydrogenase (NADP+) EC 1.1.1.135: GDP-6-deoxy-D-talose 4-dehydrogenase EC 1.1.1.136: UDP-N-acetylglucosamine 6-dehydrogenase EC 1.1.1.137: ribitol-5-phosphate 2-dehydrogenase EC 1.1.1.138: mannitol 2-dehydrogenase (NADP+) EC 1.1.1.139: polyol dehydrogenase (NADP+). Now included with EC 1.1.1.21 aldehyde reductase EC 1.1.1.140: sorbitol-6-phosphate 2-dehydrogenase EC 1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+) EC 1.1.1.142: D-pinitol dehydrogenase EC 1.1.1.143: sequoyitol dehydrogenase EC 1.1.1.144: perillyl-alcohol dehydrogenase EC 1.1.1.145: 3β-hydroxy-Δ5-steroid dehydrogenase EC 1.1.1.146: 11β-hydroxysteroid dehydrogenase EC 1.1.1.147: 16α-hydroxysteroid dehydrogenase EC 1.1.1.148: estradiol 17α-dehydrogenase EC 1.1.1.149: 20α-hydroxysteroid dehydrogenase EC 1.1.1.150: 21-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.151: 21-hydroxysteroid dehydrogenase (NADP+) EC 1.1.1.152: 3α-hydroxy-5β-androstane-17-one 3α-dehydrogenase EC 1.1.1.153: sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) EC 1.1.1.154: ureidoglycolate dehydrogenase EC 1.1.1.155: homoisocitrate dehydrogenase. The enzyme is identical to EC 1.1.1.87, homoisocitrate dehydrogenase EC 1.1.1.156: glycerol 2-dehydrogenase (NADP+) EC 1.1.1.157: 3-hydroxybutyryl-CoA dehydrogenase EC 1.1.1.158: Now EC 1.3.1.98, UDP-N-acetylmuramate dehydrogenase EC 1.1.1.159: 7α-hydroxysteroid dehydrogenase EC 1.1.1.160: dihydrobunolol dehydrogenase EC 1.1.1.161: The activity is part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.1.1.162: erythrulose reductase EC 1.1.1.163: cyclopentanol dehydrogenase EC 1.1.1.164: hexadecanol dehydrogenase EC 1.1.1.165: 2-alkyn-1-ol dehydrogenase EC 1.1.1.166: hydroxycyclohexanecarboxylate dehydrogenase EC 1.1.1.167: hydroxymalonate dehydrogenase EC 1.1.1.168: 2-dehydropantolactone reductase (Re-specific) EC 1.1.1.169: 2-dehydropantoate 2-reductase EC 1.1.1.170: 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.171: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.172: 2-oxoadipate reductase EC 1.1.1.173: L-rhamnose 1-dehydrogenase EC 1.1.1.174: cyclohexane-1,2-diol dehydrogenase EC 1.1.1.175: D-xylose 1-dehydrogenase EC 1.1.1.176: 12α-hydroxysteroid dehydrogenase EC 1.1.1.177: glycerol-3-phosphate 1-dehydrogenase (NADP+) EC 1.1.1.178: 3-hydroxy-2-methylbutyryl-CoA dehydrogenase EC 1.1.1.179: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,5-lactone-forming) EC 1.1.1.180: Now included with EC 1.1.1.131 mannuronate reductase EC 1.1.1.181: cholest-5-ene-3β,7α-diol 3β-dehydrogenase EC 1.1.1.182: Now included with EC 1.1.1.198 (+)-borneol dehydrogenase, EC 1.1.1.227 (-)-borneol dehydrogenase and EC 1.1.1.228 (+)-sabinol dehydrogenase EC 1.1.1.183: geraniol dehydrogenase (NADP+) EC 1.1.1.184: carbonyl reductase (NADPH) EC 1.1.1.185: L-glycol dehydrogenase EC 1.1.1.186: dTDP-galactose 6-dehydrogenase EC 1.1.1.187: GDP-4-dehydro-D-rhamnose reductase EC 1.1.1.188: prostaglandin-F synthase EC 1.1.1.189: prostaglandin-E2 9-reductase EC 1.1.1.190: indole-3-acetaldehyde reductase (NADH) EC 1.1.1.191: indole-3-acetaldehyde reductase (NADPH) EC 1.1.1.192: long-chain-alcohol dehydrogenase EC 1.1.1.193: 5-amino-6-(5-phosphoribosylamino)uracil reductase EC 1.1.1.194: coniferyl-alcohol dehydrogenase EC 1.1.1.195: cinnamyl-alcohol dehydrogenase EC 1.1.1.196: 15-hydroxyprostaglandin-D dehydrogenase (NADP+) EC 1.1.1.197: 15-hydroxyprostaglandin dehydrogenase (NADP+) EC 1.1.1.198: (+)-borneol dehydrogenase EC 1.1.1.199: (S)-usnate reductase EC 1.1.1.200: aldose-6-phosphate reductase (NADPH) EC 1.1.1.228: (+)-sabinol dehydrogenase EC 1.1.1.251: galactitol-1-phosphate 5-dehydrogenase EC 1.1.1.252: tetrahydroxynaphthalene reductase EC 1.1.1.253: Now EC 1.5.1.33, pteridine reductase EC 1.1.1.254: (S)-carnitine 3-dehydrogenase EC 1.1.1.255: mannitol dehydrogenase EC 1.1.1.256: fluoren-9-ol dehydrogenase EC 1.1.1.257: 4-(hydroxymethyl)benzenesulfonate dehydrogenase EC 1.1.1.258: 6-hydroxyhexanoate dehydrogenase EC 1.1.1.259: 3-hydroxypimeloyl-CoA dehydrogenase EC 1.1.1.260: sulcatone reductase EC 1.1.1.261: sn-glycerol-1-phosphate dehydrogenase EC 1.1.1.262: 4-hydroxythreonine-4-phosphate dehydrogenase EC 1.1.1.263: 1,5-anhydro-D-fructose reductase EC 1.1.1.264: L-idonate 5-dehydrogenase EC 1.1.1.265: 3-methylbutanal reductase EC 1.1.1.266: dTDP-4-dehydro-6-deoxyglucose reductase EC 1.1.1.267: 1-deoxy-D-xylulose-5-phosphate reductoisomerase EC 1.1.1.268: 2-(R)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.269: 2-(S)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.270: 3β-hydroxysteroid 3-dehydrogenase EC 1.1.1.271: GDP-L-fucose synthase EC 1.1.1.272: D-2-hydroxyacid dehydrogenase (NADP+) EC 1.1.1.273: vellosimine dehydrogenase EC 1.1.1.274: 2,5-didehydrogluconate reductase (2-dehydro-D-gluconate-forming) EC 1.1.1.275: (+)-trans-carveol dehydrogenase EC 1.1.1.276: serine 3-dehydrogenase (NADP+) EC 1.1.1.277: 3β-hydroxy-5β-steroid dehydrogenase EC 1.1.1.278: 3β-hydroxy-5α-steroid dehydrogenase EC 1.1.1.279: (R)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.280: (S)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.281: GDP-4-dehydro-6-deoxy-D-mannose reductase EC 1.1.1.282: Quinate/shikimate dehydrogenase EC 1.1.1.283: methylglyoxal reductase (NADPH-dependent) EC 1.1.1.284: S-(hydroxymethyl)glutathione dehydrogenase EC 1.1.1.285: 3′′-deamino-3′′-oxonicotianamine reductase EC 1.1.1.286: isocitrate—homoisocitrate dehydrogenase EC 1.1.1.287: D-arabinitol dehydrogenase (NADP+) EC 1.1.1.288: xanthoxin dehydrogenase EC 1.1.1.289: sorbose reductase EC 1.1.1.290: 4-phosphoerythronate dehydrogenase EC 1.1.1.291: 2-hydroxymethylglutarate dehydrogenase EC 1.1.1.292: 1,5-anhydro-D-fructose reductase (1,5-anhydro-D-mannitol-forming) EC 1.1.1.293: tropinone reductase I. This enzyme was already in the Enzyme List as EC 1.1.1.206, tropine dehydrogenase so EC 1.1.1.293 has been withdrawn at the public-review stage EC 1.1.1.294: chlorophyll(ide) b reductase EC 1.1.1.295: momilactone-A synthase EC 1.1.1.296: dihydrocarveol dehydrogenase EC 1.1.1.297: limonene-1,2-diol dehydrogenase EC 1.1.1.298: 3-hydroxypropionate dehydrogenase (NADP+) EC 1.1.1.299: malate dehydrogenase [NAD(P)+)] EC 1.1.1.300: NADP-retinol dehydrogenase EC 1.1.1.301: D-arabitol-phosphate dehydrogenase EC 1.1.1.302: 2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5′-phosphate reductase EC 1.1.1.303: Diacetyl reductase ((R)-acetoin forming) EC 1.1.1.304: Diacetyl reductase ((S)-acetoin forming) EC 1.1.1.305: UDP-glucuronic acid dehydrogenase (UDP-4-keto-hexauronic acid decarboxylating) EC 1.1.1.306: S-(hydroxymethyl)mycothiol dehydrogenase EC 1.1.1.307: D-xylose reductase EC 1.1.1.308: sulfopropanediol 3-dehydrogenase EC 1.1.1.309: phosphonoacetaldehyde reductase (NADH) EC 1.1.1.310: (S)-sulfolactate dehydrogenase EC 1.1.1.311: (S)-1-phenylethanol dehydrogenase EC 1.1.1.312: 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.1.1.313: sulfoacetaldehyde reductase EC 1.1.1.314: Now known to be catalyzed by EC 1.14.14.95, germacrene A hydroxylase EC 1.1.1.315: 11-cis-retinol dehydrogenase EC 1.1.1.316: L-galactose 1-dehydrogenase EC 1.1.1.317: perakine reductase EC 1.1.1.318: eugenol synthase EC 1.1.1.319: isoeugenol synthase EC 1.1.1.320: benzil reductase [(S)-benzoin forming] EC 1.1.1.321: benzil reductase [(R)-benzoin forming] EC 1.1.1.322: (–)-endo-fenchol dehydrogenase EC 1.1.1.323: (+)-thujan-3-ol dehydrogenase EC 1.1.1.324: 8-hydroxygeraniol dehydrogenase EC 1.1.1.325: sepiapterin reductase (L-threo-7,8-dihydrobiopterin forming) EC 1.1.1.326: zerumbone synthase EC 1.1.1.327: 5-exo-hydroxycamphor dehydrogenase EC 1.1.1.328: nicotine blue oxidoreductase EC 1.1.1.329: 2-deoxy-scyllo-inosamine dehydrogenase EC 1.1.1.330: very-long-chain 3-oxoacyl-CoA reductase EC 1.1.1.331: secoisolariciresinol dehydrogenase EC 1.1.1.332: chanoclavine-I dehydrogenase EC 1.1.1.333: decaprenylphospho-β-D-erythro-pentofuranosid-2-ulose 2-reductase EC 1.1.1.334: methylecgonone reductase EC 1.1.1.335: UDP-N-acetyl-2-amino-2-deoxyglucuronate dehydrogenase EC 1.1.1.336: UDP-N-acetyl-D-mannosamine dehydrogenase EC 1.1.1.337: L-2-hydroxycarboxylate dehydrogenase (NAD+) EC 1.1.1.338: (2R)-3-sulfolactate dehydrogenase (NADP+) EC 1.1.1.339: dTDP-6-deoxy-L-talose 4-dehydrogenase (NAD+) EC 1.1.1.340: 1-deoxy-11β-hydroxypentalenate dehydrogenase EC 1.1.1.341: CDP-abequose synthase EC 1.1.1.342: CDP-paratose synthase EC 1.1.1.343: phosphogluconate dehydrogenase (NAD+-dependent, decarboxylating) EC 1.1.1.344: dTDP-6-deoxy-L-talose 4-dehydrogenase [NAD(P)+] EC 1.1.1.345: D-2-hydroxyacid dehydrogenase (NAD+) EC 1.1.1.346: 2,5-didehydrogluconate reductase (2-dehydro-L-gulonate-forming) EC 1.1.1.347: geraniol dehydrogenase (NAD+) EC 1.1.1.348: (3R)-2′-hydroxyisoflavanone reductase EC 1.1.1.349: norsolorinic acid ketoreductase EC 1.1.1.350: ureidoglycolate dehydrogenase (NAD+) EC 1.1.1.351: phosphogluconate dehydrogenase [NAD(P)+-dependent, decarboxylating] EC 1.1.1.352: 5′-hydroxyaverantin dehydrogenase EC 1.1.1.353: versiconal hemiacetal acetate reductase EC 1.1.1.354: farnesol dehydrogenase (NAD+) EC 1.1.1.355: 2′-dehydrokanamycin reductase EC 1.1.1.356: GDP-L-colitose synthase EC 1.1.1.357: 3α-hydroxysteroid 3-dehydrogenase EC 1.1.1.358: 2-dehydropantolactone reductase EC 1.1.1.359: aldose 1-dehydrogenase [NAD(P)+] EC 1.1.1.360: glucose/galactose 1-dehydrogenase EC 1.1.1.361: glucose-6-phosphate 3-dehydrogenase EC 1.1.1.362: aklaviketone reductase EC 1.1.1.363: glucose-6-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.364: dTDP-4-dehydro-6-deoxy-α-D-gulose 4-ketoreductase EC 1.1.1.365: D-galacturonate reductase EC 1.1.1.366: L-idonate 5-dehydrogenase (NAD+) EC 1.1.1.367: UDP-2-acetamido-2,6-β-L-arabino-hexul-4-ose reductase EC 1.1.1.368: 6-hydroxycyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.1.1.369: D-chiro-inositol 1-dehydrogenase EC 1.1.1.370: scyllo-inositol 2-dehydrogenase (NAD+) EC 1.1.1.371: scyllo-inositol 2-dehydrogenase (NADP+) EC 1.1.1.372: D/L-glyceraldehyde reductase EC 1.1.1.373: sulfolactaldehyde 3-reductase EC 1.1.1.374: UDP-N-acetylglucosamine 3-dehydrogenase EC 1.1.1.375: L-2-hydroxycarboxylate dehydrogenase [NAD(P)+] EC 1.1.1.376: L-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.377: L-rhamnose 1-dehydrogenase (NADP+) EC 1.1.1.378: L-rhamnose 1-dehydrogenase [NAD(P)+] EC 1.1.1.379: (R)-mandelate dehydrogenase EC 1.1.1.380: L-gulonate 5-dehydrogenase EC 1.1.1.381: 3-hydroxy acid dehydrogenase EC 1.1.1.382: ketol-acid reductoisomerase (NAD+) EC 1.1.1.383: ketol-acid reductoisomerase [NAD(P)+] EC 1.1.1.384: dTDP-3,4-didehydro-2,6-dideoxy-α-D-glucose 3-reductase EC 1.1.1.385: dihydroanticapsin dehydrogenase EC 1.1.1.386: ipsdienol dehydrogenase EC 1.1.1.387: L-serine 3-dehydrogenase (NAD+) EC 1.1.1.388: glucose-6-phosphate dehydrogenase (NAD+) EC 1.1.1.389: 2-dehydro-3-deoxy-L-galactonate 5-dehydrogenase EC 1.1.1.390: sulfoquinovose 1-dehydrogenase EC 1.1.1.391: 3β-hydroxycholanate 3-dehydrogenase (NAD+) EC 1.1.1.392: 3α-hydroxycholanate dehydrogenase (NADP+) EC 1.1.1.393: 3β-hydroxycholanate 3-dehydrogenase (NADP+) EC 1.1.1.394: aurachin B dehydrogenase EC 1.1.1.395: 3α-hydroxy bile acid-CoA-ester 3-dehydrogenase EC 1.1.1.396: bacteriochlorophyllide a dehydrogenase EC 1.1.1.397: β-methylindole-3-pyruvate reductase EC 1.1.1.398: 2-glutathionyl-2-methylbut-3-en-1-ol dehydrogenase EC 1.1.1.399: 2-oxoglutarate reductase EC 1.1.1.400: 2-methyl-1,2-propanediol dehydrogenase EC 1.1.1.401: 2-dehydro-3-deoxy-L-rhamnonate dehydrogenase (NAD+) EC 1.1.1.402: D-erythritol 1-phosphate dehydrogenase EC 1.1.1.403: D-threitol dehydrogenase (NAD+) EC 1.1.1.404: tetrachlorobenzoquinone reductase EC 1.1.1.405: ribitol-5-phosphate 2-dehydrogenase (NADP+) EC 1.1.1.406: galactitol 2-dehydrogenase (L-tagatose-forming) EC 1.1.1.407: D-altritol 5-dehydrogenase EC 1.1.1.408: 4-phospho-D-threonate 3-dehydrogenase EC 1.1.1.409: 4-phospho-D-erythronate 3-dehydrogenase EC 1.1.1.410: D-erythronate 2-dehydrogenase EC 1.1.1.411: L-threonate 2-dehydrogenase EC 1.1.1.412: 2-alkyl-3-oxoalkanoate reductase EC 1.1.1.413: A-factor type γ-butyrolactone 1′-reductase (1S-forming) EC 1.1.1.414: L-galactonate 5-dehydrogenase EC 1.1.1.415: noscapine synthase EC 1.1.1.416: isopyridoxal dehydrogenase (5-pyridoxolactone-forming) EC 1.1.1.417: 3β-hydroxysteroid-4β-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.418: plant 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.419: nepetalactol dehydrogenase EC 1.1.1.420: D-apiose dehydrogenase EC 1.1.1.421: D-apionate oxidoisomerase EC 1.1.1.422: pseudoephedrine dehydrogenase EC 1.1.1.423: (1R,2S)-ephedrine 1-dehydrogenase EC 1.1.1.424: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,4-lactone-forming) EC 1.1.1.425: levoglucosan dehydrogenase EC 1.1.1.426: UDP-N-acetyl-α-D-quinovosamine dehydrogenase
In dental anatomy, the apical foramen, literally translated "small opening of the apex," is the tooth's natural opening, found at the root's very tip—that is, the root apex — whereby an artery, vein, and nerve enter the tooth and commingle with the tooth's internal soft tissue, called pulp. Additionally, the apical foramen is the point where the pulp meets the periodontal tissues, the connective tissues that surround and support the tooth. The foramen is located 0.5mm to 1.5mm from the apex of the tooth. Each tooth has an apical foramen.
Sources: en.wikipedia.org
=== Imprisonment === In 2000 and 2001, Pudzianowski spent 19 months in Łowicz prison for assault. In an interview, he said he wanted to stop a "local mafia boss", and he got accused of assault and stealing his golden chain. Pudzianowski was incarcerated in prison in Łowicz. Several years later he arranged a resocialization meeting for the prisoners at the same penal institution.
In Cantonese cuisine, a common method is to cook it with spices over low heat until tender, and is commonly served with noodles in soup or curry. In Korean cuisine, traditionally it is first boiled at low temperature with aromatic vegetables, then pressed with a heavy object in a container full of a soy sauce-based marinade. The ensuing preserved meat is served in match-length strips as an accompaniment (banchan) to a meal. This is called jang-jorim. Brisket is also the main ingredient in a spicy soup called yukgaejang, part of the class of soups that are complete meals in Korean cuisine. Nowadays, it is also popular to cook thin slices of it quickly over a hot plate. In Thai cuisine, it is used to prepare suea rong hai, a popular grilled dish originally from Isan in northeastern Thailand. In New Zealand cuisine, it is used in a boil up. Boiled in seasoned water with green vegetables and potatoes, it is popular amongst Māori people. It is a common cut of meat used in Vietnamese phở soup. In Italian cuisine, brisket is used to prepare bollito misto, a typical Northern Italy recipe. On the Indian subcontinent, it is used in nihari, a popular dish.
== History and evaluation == Krebiozen was initially promoted by Stevan Durovic, a Yugoslavian physician who claimed that the substance was isolated from the blood serum of horses inoculated with Actinomyces bovis. Durovic claimed that Krebiozen had been useful in the treatment of cancer, mainly in cats and dogs. His claims were backed by Andrew Conway Ivy, a prominent physiologist, and by several politicians including Senator Paul Douglas (D-IL). Ivy became convinced that Krebiozen possessed anti-cancer properties, administered the substance to himself and colleagues, then to a dog, and eventually started testing Krebiozen on patients. Ivy called a press conference in 1951 at which he announced to an audience of journalists, politicians, doctors and potential investors that Krebiozen was a success. At the press conference, Ivy claimed that of 22 treated patients, 14 were alive and none had died of cancer. However, in reality 10 of the treated patients had died—all of cancer—at the time of the press conference. Shortly afterward, the Krebiozen Research Foundation was established by the Durovic brothers, with Ivy as president. Intrigued by Ivy's announcement, 10 hospitals and cancer research centers followed up on the trial and attempted to reproduce Ivy's claimed results. None of these independent researchers observed any effect of Krebiozen on cancer. A compilation of these institutions' negative data was reported in the Journal of the American Medical Association in 1951. Krebiozen's backers responded by alleging a conspiracy against the drug.
are the concentrations of aroma compounds in the interface and emulsion, respectively. With respect to stripping, Agc has the greatest effect on the mass transfer rate. Maximizing the surface area for mass transfer is done by using the smallest bubbles possible when stripping. Assuming spherical structure of the bubbles, the surface area is given by
Complete blood count and reticulocyte count; in active G6PD deficiency, Heinz bodies can be seen in red blood cells on a blood film; Liver enzymes (to exclude other causes of jaundice); Lactate dehydrogenase (elevated in hemolysis and a marker of hemolytic severity) Haptoglobin (decreased in hemolysis); A "direct antiglobulin test" (Coombs' test) – this should be negative, as hemolysis in G6PD is not immune-mediated; When there are sufficient grounds to suspect G6PD, a direct test for G6PD is the "Beutler fluorescent spot test", which has largely replaced an older test (the Motulsky dye-decolouration test). Other possibilities are direct DNA testing and/or sequencing of the G6PD gene. The Beutler fluorescent spot test is a rapid and inexpensive test that visually identifies NADPH produced by G6PD under ultraviolet light. When the blood spot does not fluoresce, the test is positive; it can be falsely negative in patients who are actively hemolysing. It can therefore only be done 2–3 weeks after a hemolytic episode. When a macrophage in the spleen identifies an RBC with a Heinz body, it removes the precipitate and a small piece of the membrane, leading to characteristic "bite cells". However, if a large number of Heinz bodies are produced, as occurs in G6PD deficiency, some Heinz bodies will be visible when viewing RBCs stained with crystal violet. This easy and inexpensive test can lead to an initial presumption of G6PD deficiency, which can be confirmed with the other tests.
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.